Autoinflammatory & rare systemic diseases
Adult-onset Still’s disease: analysis of a monocentric cohort of patients
Authors' conclusion
The analysis of this cohort confirms that AOSD is a complex, severe, and heterogeneous disease. However, despite long-term treatment and comorbidities, therapies are effective and well tolerated.
Study context
- Population
- Patients attending a Clinical Immunology Unit fulfilling Yamaguchi, Fautrel, or Daghor-Abbaci classification criteria for Adult-onset Still's disease (AOSD); long follow-up
- Participants
- 38 patients
- Outcome
- Clinical features, disease course and treatment
Methodological detailsmonocentric, Clinical and serological data collected at diagnosis and every 6 months; Pouchot score calculated at every visit
- Monocentric
- Clinical and serological data collected at diagnosis and every 6 months; Pouchot score calculated at every visit
Main finding
As reported in the abstract
- Monocyclic disease course
- 25%
- Polycyclic disease course
- 35%
- Chronic articular involvement
- 40%
- Severe complications at disease onset
- 21%
- Treated with steroids
- All
- Received csDMARDs (MTX in most cases)
- 74%
- Received bDMARDs (IL-1 inhibitors in most cases)
- 71%
- Therapeutic switching for lack/loss of efficacy or adverse drug reactions
- 66%
Observational data: associations, not effects.
Original publication
Adult-onset Still’s disease: analysis of a monocentric cohort of patients. Scand J Rheumatol. Published 2 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →